Jon Faiz Kayyem bought $500K of Inhibrx Biosciences (INBX)

Executed Sep 16, disclosed Sep 17, 1 day later.

Value, as filed

$500K

5,000 sh × $100.00

Executed

Sep 16

the trade date, as filed

Disclosed

Sep 17

1 day after the trade

Return, 21 sessionsiFrom the disclosed entry session; derived

–

not yet measured

Not yet measured: the 21-session window has not closed, or the prices around it are not on record.

The filer

JK Jon Faiz Kayyem Director profile →

Jon Faiz Kayyem (Director) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Inhibrx Biosciences, Inc. (INBX). The largest single filing was $568K of INBX (5,000 sh × $113.52, as filed), executed Sep 8. The median gap between execution and disclosure was 0 days.

The name

INBX Inhibrx Biosciences, Inc. INBX · Healthcare · 7 filings in 24 months ticker →

Healthcare · Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with…

More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→

Other filings by Jon Faiz Kayyem in INBX

INBXPURCHASE Inhibrx Biosciences, Inc. $568K
5,000 sh × $113.52
Exec Sep 8
Filed Sep 8 · 5:23 PM ET INBXPURCHASE Inhibrx Biosciences, Inc. $1.5M
107,186 sh across 4 lots
Exec Nov 19 2024
Filed Nov 22 2024 · 5:30 PM ET †